^
    MET amplification
    GastroEsophageal Cancer
    crizotinib
    Sensitive
    :
    C3
    Target Oncol - 3wk
    HER-2 positive
    GastroEsophageal Cancer
    trastuzumab
    Sensitive
    :
    A2
    PD-L1 overexpression
    GastroEsophageal Cancer
    PD1 inhibitor
    Sensitive
    :
    B
    PD-L1 overexpression
    GastroEsophageal Cancer
    PD-L1 inhibitor
    Sensitive
    :
    B
    PD-L1 expression
    GastroEsophageal Cancer
    pembrolizumab
    Sensitive
    :
    C1
    HER-2 positive
    GastroEsophageal Cancer
    pembrolizumab
    Sensitive
    :
    C2
    TP53 mutation
    GastroEsophageal Cancer
    Immunotherapy
    Resistant
    :
    C3
    TET1 mutation
    GastroEsophageal Cancer
    Immunotherapy
    Sensitive
    :
    C3
    HER-2 expression
    GastroEsophageal Cancer
    ZW25
    Sensitive
    :
    C3
    PD-L1 expression
    GastroEsophageal Cancer
    Immunotherapy
    Sensitive
    :
    C3
    HER-2 overexpression
    GastroEsophageal Cancer
    RC48
    Sensitive
    :
    C3
    PD-L1 expression
    GastroEsophageal Cancer
    tislelizumab
    Sensitive
    :
    C3
    FGFR2 amplification
    GastroEsophageal Cancer
    ABSK-091
    Sensitive
    :
    C3
    TGFB1 elevation
    GastroEsophageal Cancer
    M7824
    Sensitive
    :
    C3
    HER-2 positive
    GastroEsophageal Cancer
    pembrolizumab + trastuzumab
    Sensitive
    :
    C3
    HER-2 overexpression
    GastroEsophageal Cancer
    ZW25
    Sensitive
    :
    C3
    MET amplification
    GastroEsophageal Cancer
    afatinib
    Resistant
    :
    C3
    EGFR amplification + ERBB2 amplification
    GastroEsophageal Cancer
    afatinib
    Sensitive
    :
    C3
    CFB overexpression
    GastroEsophageal Cancer
    sunitinib
    Sensitive
    :
    C3
    VEGFC-H
    GastroEsophageal Cancer
    sunitinib
    Sensitive
    :
    C3
    HER-2 positive
    GastroEsophageal Cancer
    pembrolizumab + margetuximab
    Sensitive
    :
    C3
    HER-2 mutation
    GastroEsophageal Cancer
    dasatinib
    Sensitive
    :
    D
    HER-2 mutation
    GastroEsophageal Cancer
    neratinib
    Sensitive
    :
    D
    HER-2 mutation
    GastroEsophageal Cancer
    dasatinib + neratinib
    Sensitive
    :
    D
    BCL2 overexpression + MCL1 overexpression
    GastroEsophageal Cancer
    AT 101
    Sensitive
    :
    D
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES